Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Jill Roberts Center for Inflammatory Bowel Disease
Explore this Website
Home
About Us
Toggle About Us menu options
Clinical Staff
Research Staff
Contact Us
Newsworthy
Toggle Newsworthy menu options
News and Announcements
Patient Care
Toggle Patient Care menu options
Clinical Services
FAQs
For Your Visit
COVID-19 Information
Nutrition Science
Toggle Nutrition Science menu options
Nutrition FAQs
Food Intolerances
News in IBD Nutrition
Research and Clinical Trials
Toggle Research and Clinical Trials menu options
Clinical Trials
Publications
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
Newsworthy
Patient Care
Nutrition Science
Research and Clinical Trials
Home
Publications
Publications
Clinical Trials
Publications
Publications
Found 37 results
Author
Title
Type
[
Year
]
Filters:
First Letter Of Last Name
is
J
[Clear All Filters]
2021
Viladomiu M
,
Metz ML
,
Lima SF
,
Jin W-B
,
Chou L
,
Guo C-J
,
Diehl GE
,
Simpson KW
,
Scherl EJ
,
Longman RS
. 2021.
Adherent-invasive E. coli metabolism of propanediol in Crohn's disease regulates phagocytes to drive intestinal inflammation.
.
Cell Host Microbe.
Viladomiu M
,
Metz ML
,
Lima SF
,
Jin W-B
,
Chou L
,
Guo C-J
,
Diehl GE
,
Simpson KW
,
Scherl EJ
,
Longman RS
. 2021.
Adherent-invasive E. coli metabolism of propanediol in Crohn's disease regulates phagocytes to drive intestinal inflammation.
.
Cell Host Microbe.
Yarur AJ
,
Deepak P
,
Casteele NVande
,
Battat R
,
Jain A
,
Okada L
,
Osterman M
,
Regueiro M
. 2021.
Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases.
.
Dig Dis Sci. 66(10):3563-3569.
Battat R
,
Lukin D
,
Scherl EJ
,
Pola S
,
Kumar A
,
Okada L
,
Yang L
,
Jain A
,
Siegel CA
. 2021.
Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease.
.
Inflamm Bowel Dis. 27(9):1443-1451.
Ma C
,
Sedano R
,
Almradi A
,
Casteele NVande
,
Parker CE
,
Guizzetti L
,
Schaeffer DF
,
Riddell RH
,
Pai RK
,
Battat R
et al.
. 2021.
An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials.
.
Gastroenterology. 160(7):2291-2302.
Lukin DJ
,
Funez-dePagnier G
,
Lima S
,
Lai D
,
Duenas-Bianchi L
,
Ahmed W
,
Jacob V
,
Battat R
,
Scherl E
,
Longman RS
. 2021.
No Durable Impact of COVID-19 on Intestinal Disease Activity in Subjects With IBD.
.
Clin Gastroenterol Hepatol. 19(11):2312-2314.e3.
Sedano R
,
Hogan M
,
Nguyen TM
,
Chang J
,
Zou GY
,
Macdonald JK
,
Casteele NVande
,
Hanzel J
,
Crowley E
,
Battat R
et al.
. 2021.
Systematic review and Meta-analysis: Clinical, Endoscopic, Histologic and Safety Placebo Rates in Induction and Maintenance trials of Ulcerative Colitis.
.
J Crohns Colitis.
Lima S
,
Gogokhia L
,
Viladomiu M
,
Chou L
,
Putzel G
,
Jin W
,
Pires S
,
Guo C-J
,
Gerardin Y
,
Crawford CV
et al.
. 2021.
Transferable Immunoglobulin A-Coated Odoribacter splanchnicus in Responders to Fecal Microbiota Transplantation for Ulcerative Colitis Limits Colonic Inflammation.
.
Gastroenterology.
Lima S
,
Gogokhia L
,
Viladomiu M
,
Chou L
,
Putzel G
,
Jin W
,
Pires S
,
Guo C-J
,
Gerardin Y
,
Crawford CV
et al.
. 2021.
Transferable Immunoglobulin A-Coated Odoribacter splanchnicus in Responders to Fecal Microbiota Transplantation for Ulcerative Colitis Limits Colonic Inflammation.
.
Gastroenterology.
2020
Lukin DJ
,
Kumar A
,
Hajifathalian K
,
Sharaiha RZ
,
Scherl EJ
,
Longman RS
. 2020.
Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease.
.
Gastroenterology. 159(4):1541-1544.e2.
Dulai PS
,
Singh S
,
Casteele NVande
,
Meserve J
,
Winters A
,
Chablaney S
,
Aniwan S
,
Shashi P
,
Kochhar G
,
Weiss A
et al.
. 2020.
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.
.
Clin Gastroenterol Hepatol. 18(13):2952-2961.e8.
Dulai PS
,
Battat R
,
Barsky M
,
Nguyen NH
,
Ma C
,
Narula N
,
Mosli M
,
Casteele NVande
,
Boland BS
,
Prokop L
et al.
. 2020.
Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors.
.
Am J Gastroenterol. 115(6):885-894.
2019
Battat R
,
Ma C
,
Jairath V
,
Khanna R
,
Feagan BG
. 2019.
Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.
.
Drug Saf. 42(5):617-632.
Battat R
,
Dulai PS
,
Casteele NVande
,
Evans E
,
Hester KD
,
Webster E
,
Jain A
,
Proudfoot JA
,
Mairalles A
,
Neill J
et al.
. 2019.
Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis.
.
Inflamm Bowel Dis. 25(2):410-420.
Lukin DJ
,
Lawlor G
,
Hudesman DP
,
Durbin L
,
Axelrad JE
,
Passi M
,
Cavaliere K
,
Coburn E
,
Loftus M
,
Jen H
et al.
. 2019.
Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile.
.
Inflamm Bowel Dis. 25(4):775-781.
Gogokhia L
,
Buhrke K
,
Bell R
,
Hoffman B
,
D Brown G
,
Hanke-Gogokhia C
,
Ajami NJ
,
Wong MC
,
Ghazaryan A
,
Valentine JF
et al.
. 2019.
Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis.
.
Cell Host Microbe. 25(2):285-299.e8.
Battat R
,
Duijvestein M
,
Guizzetti L
,
Choudhary D
,
Boland BS
,
Dulai PS
,
Parker CE
,
Nguyen TM
,
Singh S
,
Casteele NVande
et al.
. 2019.
Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
.
Am J Gastroenterol. 114(5):733-745.
Ma C
,
Battat R
,
Dulai PS
,
Parker CE
,
Sandborn WJ
,
Feagan BG
,
Jairath V
. 2019.
Innovations in Oral Therapies for Inflammatory Bowel Disease.
.
Drugs. 79(12):1321-1335.
2018
Borges LF
,
Jagadeesan V
,
Goldberg H
,
Gavini S
,
Lo W-K
,
Burakoff R
,
Feldman N
,
Chan WW
. 2018.
Abnormal Bolus Reflux Is Associated With Poor Pulmonary Outcome in Patients With Idiopathic Pulmonary Fibrosis.
.
J Neurogastroenterol Motil. 24(3):395-402.
Dulai PS
,
Boland BS
,
Singh S
,
Chaudrey K
,
Koliani-Pace JL
,
Kochhar G
,
Parikh MP
,
Shmidt E
,
Hartke J
,
Chilukuri P
et al.
. 2018.
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.
.
Gastroenterology. 155(3):687-695.e10.
Dogan B
,
Belcher-Timme HFacey
,
Dogan EI
,
Jiang Z-D
,
Dupont HL
,
Snyder N
,
Yang S
,
Chandler B
,
Scherl EJ
,
Simpson KW
. 2018.
Evaluation of Escherichia coli pathotypes associated with irritable bowel syndrome.
.
FEMS Microbiol Lett. 365(22)
Ghosh G
,
Jacob V
,
Wan D
. 2018.
Plasmablastic Lymphoma in a Patient With Crohn's Disease After Extensive Immunosuppressive Therapy.
.
Clin Gastroenterol Hepatol. 16(4):e41-e42.
Battat R
,
Duijvestein M
,
Casteele NVande
,
Singh S
,
Dulai PS
,
Valasek MA
,
Mimms L
,
McFarland J
,
Hester KD
,
Renshaw M
et al.
. 2018.
Serum Concentrations of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease.
.
Clin Gastroenterol Hepatol.
2017
Battat R
,
Kopylov U
,
Bessissow T
,
Bitton A
,
Cohen A
,
Jain A
,
Martel M
,
Seidman E
,
Afif W
. 2017.
Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
.
Clin Gastroenterol Hepatol. 15(9):1427-1434.e2.
Viladomiu M
,
Kivolowitz C
,
Abdulhamid A
,
Dogan B
,
Victorio D
,
Castellanos JG
,
Woo V
,
Teng F
,
Tran NL
,
Sczesnak A
et al.
. 2017.
IgA-coated enriched in Crohn's disease spondyloarthritis promote T17-dependent inflammation.
.
Sci Transl Med. 9(376)
1
(current)
2
next ›
last »